{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:13:12Z","timestamp":1767625992592},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,4,27]],"date-time":"2014-04-27T00:00:00Z","timestamp":1398556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s12253-014-9777-7","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T12:43:55Z","timestamp":1398516235000},"page":"939-944","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Psychological Changes in Melanoma Patients During Ipilimumab Treatment Compared to Low-Dose Interferon Alpha Therapy\u2014A Follow-Up Study of First Experiences"],"prefix":"10.1007","volume":"20","author":[{"given":"P\u00e9ter","family":"Kov\u00e1cs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitta","family":"P\u00e1ncz\u00e9l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Borbola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Juh\u00e1sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Liszkay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,27]]},"reference":[{"issue":"4","key":"9777_CR1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clon.2011.12.002","volume":"26","author":"T Petrella","year":"2012","unstructured":"Petrella T, Verma S, Spithoff K, McCready D (2012) Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol 26(4):413\u2013423","journal-title":"Clin Oncol"},{"issue":"85","key":"9777_CR2","first-page":"1","volume":"445","author":"V Gray-Schopfer","year":"2007","unstructured":"Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445(85):1\u20137","journal-title":"Nature"},{"key":"9777_CR3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","volume":"102","author":"S Mocellin","year":"2010","unstructured":"Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493\u2013501","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"9777_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clindermatol.2008.09.001","volume":"27","author":"C Garbe","year":"2009","unstructured":"Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27(1):3\u20139","journal-title":"Clin Dermatol"},{"key":"9777_CR5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998\u20131012","journal-title":"N Engl J Med"},{"key":"9777_CR6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/era.09.25","volume":"9","author":"SS Agarwala","year":"2009","unstructured":"Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587\u2013595","journal-title":"Expert Rev Anticancer Ther"},{"key":"9777_CR7","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1200\/JCO.1996.14.7.2083","volume":"14","author":"JJ Rusthoven","year":"1996","unstructured":"Rusthoven JJ, Quirt IC, Iscoe NA et al (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083\u20132090","journal-title":"J Clin Oncol"},{"key":"9777_CR8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158\u2013166","journal-title":"J Clin Oncol"},{"key":"9777_CR9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","volume":"106","author":"S Verma","year":"2006","unstructured":"Verma S, Quirt I, McCready D, Bak K, Charrette M, Iscoe N (2006) Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106:1431\u20131442","journal-title":"Cancer"},{"issue":"26","key":"9777_CR10","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526","journal-title":"N Engl J Med"},{"key":"9777_CR11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"9777_CR12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2012.06.013","volume":"48","author":"C Garbe","year":"2012","unstructured":"Garbe C, Peris K, Hauschild A et al (2012) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline\u2013update. Eur J Cancer 48:2375\u20132390","journal-title":"Eur J Cancer"},{"issue":"suppl 18","key":"9777_CR13","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1200\/jco.2007.25.18_suppl.8526","volume":"25","author":"K Wheatley","year":"2007","unstructured":"Wheatley K, Ives N, Eggermont A, on behalf of International Malignant Melanoma Collaborative Group et al (2007) Interferon-\u03b1 as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 25(suppl 18):8526","journal-title":"J Clin Oncol"},{"key":"9777_CR14","first-page":"466","volume":"51","author":"A Friebe","year":"2010","unstructured":"Friebe A, Horn M, Schmidt F et al (2010) Dose-dependent development of depressive symptoms during adjuvant interferon treatment of patients with malignant melanoma. Psychosomatics 51:466\u2013473","journal-title":"Psychosomatics"},{"key":"9777_CR15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-0327(02)00264-1","volume":"72","author":"S Bonaccorso","year":"2002","unstructured":"Bonaccorso S, Marino V, Biondi M et al (2002) Depression induced by treatment with interferon- in patients affected by hepatitis C virus. J Affect Disord 72:237\u2013241","journal-title":"J Affect Disord"},{"key":"9777_CR16","first-page":"3","volume":"25","author":"EC Borden","year":"1998","unstructured":"Borden EC, Parkinson D (1998) A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol 25:3\u20138","journal-title":"Semin Oncol"},{"key":"9777_CR17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","volume":"157","author":"E Dieperink","year":"2000","unstructured":"Dieperink E, Willenbring M, Ho SB (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon: a review. Am J Psychiatry 157:867\u2013876","journal-title":"Am J Psychiatry"},{"key":"9777_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(85)80002-3","volume":"9","author":"N Dafny","year":"1985","unstructured":"Dafny N, Prieto-Gomez B, Reyes-Vazquez C (1985) Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity. J Neuroimmunol 9:1\u201312","journal-title":"J Neuroimmunol"},{"key":"9777_CR19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0278-5846(01)00324-4","volume":"26","author":"M Schaefer","year":"2002","unstructured":"Schaefer M, Engelbrecht MA, Gut O et al (2002) Interferon (IFN) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26:731\u2013746","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9777_CR20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archpsyc.1965.01720310065008","volume":"12","author":"WWK Zung","year":"1965","unstructured":"Zung WWK (1965) A self-rating depression scale. Arch Gen Psychiatry 12:63\u201370","journal-title":"Arch Gen Psychiatry"},{"key":"9777_CR21","first-page":"180","volume-title":"Pszichodiagnosztikai Vademecum","author":"A Simon","year":"1994","unstructured":"Simon A (1994) A Zung-f\u00e9le \u00d6n\u00e9rt\u00e9kel\u0151 Depresszi\u00f3 Sk\u00e1la. In: M\u00e9rei F, Szak\u00e1cs F (eds) Pszichodiagnosztikai Vademecum. Nemzeti Tank\u00f6nyvkiad\u00f3, Budapest, pp 180\u2013185"},{"key":"9777_CR22","volume-title":"Manual for the state-trait anxiety inventory","author":"CD Spielberger","year":"1983","unstructured":"Spielberger CD, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto"},{"key":"9777_CR23","first-page":"51","volume-title":"Cross cultural anxiety, 2","author":"K Sipos","year":"1983","unstructured":"Sipos K, Sipos M (1983) The development and validation of the Hungarian form of the STAI. In: Spielberger CD, DiazGuerro R (eds) Cross cultural anxiety, 2. Hemisphere Publishing Corporation, Washington-London, pp 51\u201361"},{"issue":"1","key":"9777_CR24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0146167287131001","volume":"13","author":"RA Caldwell","year":"1987","unstructured":"Caldwell RA, Pearson JL, Chin RJ (1987) Stress-moderating effects: social support in the context of gender and locus of control. Personal Soc Psychol Bull 13(1):5\u201317","journal-title":"Personal Soc Psychol Bull"},{"issue":"4","key":"9777_CR25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pon.3060","volume":"22","author":"L Rychetnick","year":"2012","unstructured":"Rychetnick L, McCaffery K, Morton R, Irwing L (2012) Psychosocial aspects of post-treatment follow-up for stage I\/II melanoma: a systematic review of the literature. Psychooncology 22(4):721\u2013736","journal-title":"Psychooncology"},{"key":"9777_CR26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/pon.1976","volume":"21","author":"AN Kasparian","year":"2012","unstructured":"Kasparian AN, Sansom-Daly U, McDonald RP, Meiser B, Butow PN, Mann GJ (2012) The nature and structure of psychological distress in people at high risk for melanoma: a factor analytic study. Psychooncology 21:845\u2013856","journal-title":"Psychooncology"},{"key":"9777_CR27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/foc.7.3.foc317","volume":"7","author":"F Meyer","year":"2009","unstructured":"Meyer F, Ehrlich M, Peteet J (2009) Psycho-oncology: a review for the general psychiatrist. FOCUS 7:317\u2013331","journal-title":"FOCUS"},{"key":"9777_CR28","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1002\/cncr.24561","volume":"115","author":"JR Satin","year":"2009","unstructured":"Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients. Cancer 115:5349\u20135361","journal-title":"Cancer"},{"key":"9777_CR29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.1993.01820210015002","volume":"50","author":"IF Fawzy","year":"1993","unstructured":"Fawzy IF, Fawzy NW, Hyun CS et al (1993) Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6\u00a0years later. Arch Gen Psychiatry 50:681\u2013689","journal-title":"Arch Gen Psychiatry"},{"issue":"9633","key":"9777_CR30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","volume":"372","author":"AM Eggermont","year":"2008","unstructured":"Eggermont AM, Suciu S, Santinami M, EORTC Melanoma Group et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 372(9633):117\u2013126","journal-title":"Lancet"},{"key":"9777_CR31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/pon.770","volume":"13","author":"P Trask","year":"2004","unstructured":"Trask P, Paterson A, Esper P et al (2004) Longitudinal course of depression, fatigue, and quality of life in patients with high-risk melanoma receiving adjuvant interferon. Psychooncology 13:526\u2013536","journal-title":"Psychooncology"},{"key":"9777_CR32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","volume":"366","author":"AMM Eggermont","year":"2005","unstructured":"Eggermont AMM, Suciu S, MacKie R, for the EORTC Melanoma Group et al (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366:1189\u20131196","journal-title":"Lancet"},{"key":"9777_CR33","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","volume":"351","author":"JJ Grob","year":"1998","unstructured":"Grob JJ, Dreno B, de la Salmoniere P et al (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1,5\u00a0mm without clinically detectable node metastases. Lancet 351:1905\u20131910","journal-title":"Lancet"},{"key":"9777_CR34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.mp.4002006","volume":"12","author":"N M\u00fcller","year":"2007","unstructured":"M\u00fcller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988\u20131000","journal-title":"Mol Psychiatry"},{"issue":"suppl 1","key":"9777_CR35","first-page":"S30","volume":"25","author":"J Licinio","year":"1998","unstructured":"Licinio J, Kling MA, Hauser P (1998) Cytokines and brain function: relevance to interferon-alpha induced mood and cognitive changes. Semin Oncol 25(suppl 1):S30\u2013S38","journal-title":"Semin Oncol"},{"key":"9777_CR36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1470-2045(04)01597-9","volume":"5","author":"EMV Reiche","year":"2004","unstructured":"Reiche EMV, Nunes SOV, Morimoto HK (2004) Stress, depression, the immune system and cancer. Lancet 5:617\u2013625","journal-title":"Lancet"},{"key":"9777_CR37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","volume":"344","author":"DL Musselmann","year":"2001","unstructured":"Musselmann DL, Lawson DH, Gumnick JF et al (2001) Paroxetine for the prevention of depression induced by highdose interferon alpha. N Engl J Med 344:961\u2013966","journal-title":"N Engl J Med"},{"key":"9777_CR38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.genhosppsych.2010.03.001","volume":"32","author":"AG Almeida","year":"2010","unstructured":"Almeida AG, Guindalini C, Batista-Neves S et al (2010) Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry 32:401\u2013405","journal-title":"Gen Hosp Psychiatry"},{"key":"9777_CR39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"CL Raison","year":"2006","unstructured":"Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of major depression. Trends Immunol 27:24\u201331","journal-title":"Trends Immunol"},{"key":"9777_CR40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CJI.0b013e3181b8bdb9","volume":"33","author":"S Heinze","year":"2010","unstructured":"Heinze S, Egberts F, R\u00f6tzer S et al (2010) Depressive mood changes and psychiatric symptoms. J Immunother 33:106\u2013114","journal-title":"J Immunother"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-014-9777-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-014-9777-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-014-9777-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T11:47:50Z","timestamp":1597751270000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-014-9777-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,27]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["9777"],"URL":"https:\/\/doi.org\/10.1007\/s12253-014-9777-7","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,27]]}}}